Burnham Urged to Ditch UK-US NHS Drug Deal

Andy Burnham, the expected next Prime Minister, is facing calls from health organizations and doctors' groups to terminate the UK-US trade agreement on medicines. These groups have issued warnings that the deal is dangerous and places the profits of pharmaceutical companies above the well-being of NHS patients. The agreement, signed in December, has been defended by current ministers as a measure to help British drug exports bypass tariffs in the US and to provide patients with access to drugs that might otherwise be unavailable.

Analysis suggests the current deal could lead to a significant increase in excess deaths, potentially reaching 229,000 by 2036. This projection highlights the core concern of the health advocates: that the agreement's structure prioritizes commercial interests over public health outcomes. The organizations are advocating for a complete dismantling of the pact, emphasizing the need to protect the National Health Service from potential negative impacts on drug pricing and accessibility.

The calls for Burnham to act come amid ongoing political developments, with the UK's political landscape in flux. The urgency expressed by the health sector underscores the perceived high stakes of the agreement. The specific concerns revolve around the potential for increased drug costs and reduced availability of essential medicines if the current terms remain in place, impacting the foundational principles of the NHS.